Australia · Delayed Price · Currency is AUD Nanosonics Earnings Call Transcripts
Fiscal Year 2026
-
FY2026 delivered constant-currency revenue and EBIT growth, a larger trophon base and launches of trophon3 and trophon2 Plus. FY2027 priorities center on CORIS commercialization, further trophon growth and shareholder returns through a buyback.
-
FY 2026 saw 6% constant currency revenue growth and 21% EBIT growth, driven by record trophon placements and upgrades, disciplined cost control, and strong North American performance. CORIS is set for commercial launch in FY 2027, with significant investment and initial revenues expected in the low single-digit millions.
-
Revenue grew 9% year-over-year to AUD 102 million, with strong recurring revenue and operating margin expansion. Guidance for 8%-12% revenue growth is reaffirmed, supported by upgrades, new product launches, and disciplined cost management.
Fiscal Year 2025
-
The meeting highlighted strong financial growth, major product launches (trophon3 and CORIS), and a new share buyback. All board and remuneration resolutions passed with high support. Strategic focus remains on innovation, sustainability, and global expansion, with no dividend declared due to low franking credits.
-
Revenue grew 17% to AUD 198.6 million, with recurring revenue up 20% and profit before tax up 72%. FY 2026 guidance anticipates 8–12% revenue growth, gross margin of 75–77%, and continued investment in innovation, with minimal CORIS revenue expected.
-
Revenue rose 18% year-over-year to AUD 93.6 million, with strong growth in North America and Europe. Full-year revenue guidance was raised to 11%-14%, gross margin improved to 78.5%, and net profit increased 58%. Cash balance stands at AUD 144.5 million, with no debt.
Fiscal Year 2024
-
The meeting reviewed a return to growth in FY 2024, with strong H2 performance, robust margins, and ongoing investment in R&D and sustainability. Strategic focus remains on expanding the trophon base, launching CORIS pending FDA approval, and strengthening governance and diversity. Shareholders discussed regulatory, competitive, and operational risks.
-
Second half FY24 saw a strong revenue rebound, driven by capital unit sales and recurring revenue growth. FY25 guidance targets 8%-12% revenue growth, margin recovery, and continued investment in R&D and M&A, with hospital budget constraints easing but still present.